Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exatecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exatecan SCHEMBL29351332 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL31615015 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL29601765 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL23471938 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL2512959 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL25349032 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7249645 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL26320 | 1.00 | TOP1 (0.60) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL7163616 | 0.99 | TOP1 (0.59) | TOP1MEN1KMT2A | |
| Exatecan SCHEMBL6047672 | 0.99 | TOP1 (0.59) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381332-A1 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | BAILI BIO CHENGDU PHARMACEUTICAL CO LTD (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381332-A1 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | BAILI BIO CHENGDU PHARMACEUTICAL CO LTD (CN) | 2023-11-30 | — | — | US | disclosed |
| EP-4227309-A1 | DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Sichuan Baili Pharmaceutical Co. Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| EP-4227310-A1 | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF | Sichuan Baili Pharmaceutical Co. Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| EP-3995496-A1 | CAMPTOTHECIN DRUG AND ANTIBODY CONJUGATE THEREOF | SICHUAN BAILI PHARMACEUTICAL CO., LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022000868-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海皓元生物医药科技有限公司 | 2022-01-06 | — | — | WO | disclosed |
| EP-2197279-B1 | C10-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-8980909-B2 | HDAC inhibiting derivatives of camptothecin | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980909-B2 | HDAC inhibiting derivatives of camptothecin | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2197879-B1 | C7-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS INC (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2009051578-A1 | C10-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099166-A1 | C10-substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099166-A1 | C10-substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099224-A1 | C7- substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099224-A1 | C7- substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20080261919-A1 | Camptothecin-analog with a novel, \"flipped\" lactone-stable, E-ring and methods for making and using same | BIONUMERIK PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261919-A1 | Camptothecin-analog with a novel, \"flipped\" lactone-stable, E-ring and methods for making and using same | BIONUMERIK PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2007123995-A2 | CAMPTOTHECIN-ANALOG WITH A NOVEL, “FLIPPED” LACTONE-STABLE, E-RING AND METHODS FOR MAKING AND USING SAME | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20030109460-A1 | Medicinal composition containing camptothecin derivative and ph regulating agent | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1310254-A1 | MEDICINAL COMPOSITIONS CONTAINING CAMPTOTHECIN DERIVATIVE AND PH REGULATING AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381332-A1 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | DCTD, CD38, CDA | TOP1 34/4885MEN1 1083/4885KMT2A 876/4885 |
| US-20090099166-A1 | C10-substituted camptothecin analogs | ABCB1, ABCC1, TOP1 | TOP1 3/4885MEN1 1708/4885KMT2A 4272/4885 |
| US-20080261919-A1 | Camptothecin-analog with a novel, \"flipped\" lactone-stable, E-ring and methods for making and using same | PAICS, FAU, FOLR1 | TOP1 26/4885MEN1 141/4885KMT2A 2849/4885 |
| US-20090099224-A1 | C7- substituted camptothecin analogs | ABCB1, ABCC1, ABCG2 | TOP1 7/4885MEN1 2539/4885KMT2A 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.